The largest database of trusted experimental protocols

15 protocols using mini osmotic pump

1

Bumetanide and Bromodeoxyuridine Delivery

Check if the same lab product or an alternative is used in the 5 most similar protocols
Bumetanide (Sigma-Aldrich, B3023) (dosage of 40 mg/kg body weight/day) and bromodeoxyuridine (Sigma-Aldrich, B5002) (dosage 40 mg/kg body weight/day) were dissolved in H2O: PEG300 (1:5) with incubation on a thermo shaker on 36 °C, 1000 rpm, overnight. Mini-osmotic pumps from Alzet® (model 2001, DURECT Corporation, Cupertino, CA, USA) with a filling volume of 200 μl and a pump delivery rate of 1 μl/h were used. One day prior to pump implantation, the Mini-osmotic pumps were loaded with appropriate volume (200 μl) of the solution as directed by manufacturer using the provided needle. The loaded Mini-osmotic pumps were primed in sterile NaCl 0.9% at 37 °C overnight according to the supplier’s instruction.
+ Open protocol
+ Expand
2

Microglial Ablation Model in Glioma

Check if the same lab product or an alternative is used in the 5 most similar protocols
A model of local microglial ablation using CD11b-HSVTK transgenic mice expressing the herpes simplex thymidine kinase (HSVTK) protein in microglia and macrophages [9 (link), 36 (link)] was employed. When these animals are exposed to ganciclovir (GCV), the cells that express HSVTK are eliminated. CD11b-HSVTK (+/-) male mice (gift of Dr. Tsirka, Stonybrook University) were bred with C57BL/6 males. Offspring were genotyped by PCR using primers 5′ -GACTTCCGTGGCTTCTTGCTGC-3′ and 5′ -GTGCTGGCATTACAGGCGTGAG-3′. GL261 glioma cells were implanted into the right cerebral hemisphere of 12–16 week old CD11b-HSVTK (+/-) mice. C57BL/6 mice were used as controls. Tumors were allowed to grow for ten days and then mini-osmotic pumps (Alzet, DURECT, model 2004) were installed for local administration of GCV (Calbiochem, Billerica, MA, USA) to the tumor. Animals were anesthetized and a 3mm brain infusion cannula connected to pump was set up at the previous tumor implantation site using brain infusion kit (Alzet, DURECT). The pumps were placed subcutaneously on the mouse back. The drug was infused at 0.25 μL/h, 1 mg/mL over 7 days. Pumps with normal saline solution were used as a control.
+ Open protocol
+ Expand
3

Angiotensin II-Induced Kidney Damage Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mini-osmotic pumps were purchased from DURECT Corporation (Model 2006, Cupertino, CA). Angiotensin II (AngII), Honokiol (HKL), FITC-inulin, Bovine Serum Albumin (BSA) were purchased from Sigma Aldrich (Sigma Aldrich, USA). Mouse urine creatinine assay kit was purchased from R&D Systems (R&D, USA). Mouse urine albumin, BUN and Scr assay kit were purchased from AssayPro Corporation (AssayPro, USA). Antibodies against SIRT3 (28kDa), acetylated lysine, Tubulin and GAPDH were purchased from Cell Signaling Technology (CST, USA). Antibodies against KLF15, fibronectin, collagen type IV, synaptopodin, WT-1 were purchased from abcam (Abcam, USA).
+ Open protocol
+ Expand
4

BrdU Labeling for Tumor Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Twelve days after the inoculation, mini-osmotic pumps (Durect Corporation, Cupertino, CA, USA) containing BrdU dissolved in physiological saline (250 mg/mL) were implanted subcutaneously into the animals’ backs for 6 days to label all P cells. The percentage of labeled cells after continuous labeling with BrdU was 54.3±6.1%, and reached a plateau at this stage. Therefore, tumor cells not incorporating BrdU after continuous labeling were regarded as Q cells.
+ Open protocol
+ Expand
5

Quantifying Tumor Cell Proliferation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Two weeks after tumor cell inoculation, mini-osmotic pumps (Durect Corporation, Cupertino, CA) containing BrdU dissolved in physiological saline (250 mg/mL) were implanted subcutaneously to label all P cells for 7 days. Administration of BrdU did not change the tumor growth rate. The tumors were approximately 7 mm in diameter on treatment. The labeling index (LI) after continuous labeling with BrdU was 48.4% (41.7-55.1%) (mean (95% confidence limit)) and 43.2% (37.0-49.4%) for SAS/neo and SAS/mp53 tumor cells, respectively, and reached a plateau level at these stages. Therefore, in this study, we regarded tumor cells not incorporating BrdU after continuous labeling as Q cells.
+ Open protocol
+ Expand
6

Labeling Tumor Cells with BrdU

Check if the same lab product or an alternative is used in the 5 most similar protocols
Two weeks after tumor cell inoculation, mini-osmotic pumps (Durect Corporation, Cupertino, CA, USA) containing BrdU dissolved in physiological saline (250 mg/mL) were implanted subcutaneously to label all P cells for 7 days. Administration of BrdU did not change the tumor growth rate. The tumors were approximately 7 mm in diameter on treatment. The labeling index (LI) after continuous labeling with BrdU was 48.4% (41.7-55.1%) (mean (95% confidence limit)) and 43.2% (37.0-49.4%) for SAS/neo and SAS/mp53 tumor cells, respectively, and reached a plateau level at these stages. Therefore, in this study, we regarded tumor cells not incorporating BrdU after continuous labeling as Q cells.
+ Open protocol
+ Expand
7

Continuous BrdU Labeling of Proliferating Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Nine days after tumor inoculation, mini-osmotic pumps (Durect Corporation, Cupertino, CA) containing BrdU dissolved in physiological saline (250 mg/mL) were implanted subcutaneously to enable the labeling of all proliferating (P) cells over a 5-day period. The percentage of labeled cells after continuous labeling with BrdU was 66.1±3.8% and plateaued at this stage. Tumor cells not incorporating BrdU after continuous exposure were practically regarded as Q cells.
+ Open protocol
+ Expand
8

Insulin Delivery in High-Fat Diet Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
A cohort of mice were put on HFD at 15 weeks and subcutaneously implanted at 17 weeks with mini osmotic pumps (Alzet 2004; DURECT, Cupertino, CA, USA) designed to release murine INSULIN2 peptide (0.1 U/day; generously provided by Novo Nordisk, Bagsvaerd, Denmark) or vehicle for 28 days.
+ Open protocol
+ Expand
9

Galantamine and Pyridostigmine Treatment in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
WT mice used in this study were on the C57BL/6J background and from The Jackson Laboratory (Bar Harbor, ME, USA). Choline transporter heterozygous deficient (ChTHET) mouse breeders were provided by Dr. Randy Blakely (Florida Atlantic University, Boca Raton, FL, USA). Twelve-month-old female mice/15-month old male mice were treated daily for 6 weeks via intraperitoneal injection (i.p.) with galantamine hydrobromide (Sigma-Aldrich, St. Louis, MO, USA; G1660) at 2.5 mg/kg/day or vehicle, and were euthanized at 13.5 and 16.5 months of age. Fourteen-week-old female/male mice were treated daily for 6 weeks with galantamine hydrobromide or pyridostigmine bromide (Sigma-Aldrich; P9797) at 2.5 mg/kg/day and 1 mg/kg/day, respectively. Pyridostigmine was administered via mini-osmotic pumps implanted subcutaneously (Durect Corporation, Cupertino, CA, USA; 0000298) to reduce biohazard concerns.(38 (link)) All procedures were approved by the Institutional Animal Care and Use Committee at Baylor College of Medicine.
+ Open protocol
+ Expand
10

Labeling Tumor Cells with BrdU

Check if the same lab product or an alternative is used in the 5 most similar protocols
Nine days after the tumor cell inoculation, mini-osmotic pumps (Durect Corporation, Cupertino, CA, USA) containing BrdU dissolved in physiological saline (200-250 mg·ml−1) were implanted subcutaneously, to label all P cells, for 5 days. Administration of BrdU did not change the tumor growth rate. The tumors were 1 cm in diameter at treatment. The labeling index after continuous labeling with BrdU was 55.3 ± 4.5 (mean ± standard deviation) %, and reached a plateau level at these stages. Therefore, we regarded tumor cells not incorporating BrdU after continuous labeling as Q cells.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!